Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry

Basit Öğe Kaydı
dc.authoridHeinemann, Melina/0000-0001-7762-4696
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridBerenguer, Marina/0000-0001-9246-4264
dc.authoridBoudjema, Karim/0000-0002-3894-8767
dc.authoridZieniewicz, Krzysztof/0000-0003-4481-1289
dc.authorwosidDuvoux, Christophe/CAF-3432-2022
dc.authorwosidHeinemann, Melina/AEX-3550-2022
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidBerenguer, Marina/ABG-8602-2020
dc.authorwosidDuvoux, Christophe/CAH-9481-2022
dc.authorwosidÇoker, Ahmet/JVO-7526-2024
dc.authorwosidKaram, Vincent/HLQ-6211-2023
dc.contributor.authorHeinemann, Melina
dc.contributor.authorLiwinski, Timur
dc.contributor.authorAdam, Rene
dc.contributor.authorBerenguer, Marina
dc.contributor.authorMirza, Darius
dc.contributor.authorMalek-Hosseini, Seyed Ali
dc.contributor.authorHeneghan, Michael A.
dc.date.accessioned2024-08-04T20:50:48Z
dc.date.available2024-08-04T20:50:48Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractKnowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compared to donation after brain death (DBD) (hazard ratio [HR] = 1.95, 95% confidence interval [CI] = 1.36-2.80, p < .001). Pediatric PSC patients showed also increased mortality >90 days after LDLT compared to DBD (HR = 3.00, 95% CI 1.04-8.70, p = .043). Multivariate analysis identified several risk factors for death in adult PSC patients receiving LDLT including a male donor (HR = 2.49, p = .025). Adult PSC patients with LDLT versus DBD conferred increased mortality from disease recurrence (subdistribution hazard ratio [subHR] = 5.36, p = .001) and biliary complications (subHR = 4.40, p = .006) in multivariate analysis. While long-term outcome following LDLT for AILD is generally favorable, PSC patients with LDLT compared to DBD might be at increased risk of death.en_US
dc.description.sponsorshipAstellas Pharma; Novartis; Institut Georges Lopez; Sandozen_US
dc.description.sponsorshipThe Organ Sharing Organizations: the French ABM (Sami Djabbour), the Dutch NTS (Maaike de Wolf), the Eurotransplant Foundation (Marieke Van Meel), the Spanish RETH (Gloria de la Rosa), the UK-Ireland NHSBT (Michael Daynes), and the Scanditransplant (Ilse Duus Weinreich) are acknowledged for the data cross-check and sharing with the ELTR. The European Liver Transplant Registry is supported by a grant from Astellas Pharma, Novartis, Institut Georges Lopez, and Sandoz and receives logistical support from the Paul Brousse Hospital (AP-HP).en_US
dc.identifier.doi10.1111/ajt.16864
dc.identifier.endpage633en_US
dc.identifier.issn1600-6135
dc.identifier.issn1600-6143
dc.identifier.issue2en_US
dc.identifier.pmid34605157en_US
dc.identifier.scopus2-s2.0-85118145684en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage626en_US
dc.identifier.urihttps://doi.org/10.1111/ajt.16864
dc.identifier.urihttps://hdl.handle.net/11616/100288
dc.identifier.volume22en_US
dc.identifier.wosWOS:000709465000001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAmerican Journal of Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectclinical research/practiceen_US
dc.subjectgraft survivalen_US
dc.subjectliver diseaseen_US
dc.subjectimmuneen_US
dc.subjectinflammatoryen_US
dc.subjectliver transplantation/hepatologyen_US
dc.subjectliver transplantationen_US
dc.subjectliving donoren_US
dc.subjectpatient survivalen_US
dc.titleLong-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu